Antigen binding molecules and methods thereof II
AssigneeAgency for Science, Technology and Research
InventorsChui Ping Angela Chin, Boon Hwa Andre Choo, Wey Jia Fong, Mei Yee Vanessa Ding
Life of this patent
Estimating the term…
Abstract
The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.
Claims14
An antigen-binding molecule that specifically binds to MHC Class I DLA-12 antigen, wherein the antigen-binding molecule comprises:
- a) a heavy chain variable (VH) region comprising the VHCDR1 amino acid sequence K A S G Y T F T D Y N M H (SEQ ID NO:
- 1), the VHCDR2 amino acid sequence Y I Y P Y N G G T D Y N Q K F K (SEQ ID NO:
- 2) and the VHCDR3 amino acid sequence G G L V G A M D Y (SEQ ID NO:
- 3);
- and
- b) a light chain variable (VL) region comprising the VLCDR1 amino acid sequence R A S G N I H N S L A (SEQ ID NO:
- 4), the VLCDR2 amino acid sequence N A K T L P D (SEQ ID NO:
- 5) and the VLCDR3 amino acid sequence Q H F W S I P W T (SEQ ID NO:
- 6).
A method of treating cancer in a subject, wherein the method comprises administering a therapeutically effective amount of an antigen-binding molecule that specifically binds to MHC Class I DLA-12 to the subject, and wherein the antigen-binding molecule comprises:
- a) a heavy chain variable (VH) region comprising the VHCDR1 amino acid sequence K A S G Y T F T D Y N M H (SEQ ID NO:
- 1), the VHCDR2 amino acid sequence Y I Y P Y N G G T D Y N Q K F K (SEQ ID NO:
- 2) and the VHCDR3 amino acid sequence G G L V G A M D Y (SEQ ID NO:
- 3);
- and
- b) a light chain variable (VL) region comprising the VLCDR1 amino acid sequence R A S G N I H N S L A (SEQ ID NO:
- 4), the VLCDR2 amino acid sequence N A K T L P D (SEQ ID NO:
- 5) and the VLCDR3 amino acid sequence Q H F W S I P W T (SEQ ID NO:
- 6).
Dependencies are inferred from the claim text.